AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights:
GSK’s liquid meningitis vaccine, Menveo, has received approval from the European Commission for use in children, adolescents, and adults.
The liquid formulation eliminates the need for reconstitution, simplifying the vaccination process.
Menveo has been distributed in over 60 countries, with more than 82 million doses given since 2010.
The European Commission has granted approval for GSK’s (LSE:GSK) Menveo vaccine, a liquid formulation designed to provide active immunization against invasive meningococcal disease (IMD). This approval makes Menveo the first single-vial, fully liquid meningitis vaccine licensed for use in children aged two and older, as well as adolescents and adults. IMD is a leading cause of both meningitis and septicaemia, conditions that can lead to severe complications, including death or long-term disabilities.
The liquid version of Menveo is a significant advancement in the administration of the vaccine, as it does not require reconstitution before use. According to Philip Dormitzer, head of global vaccines R&D at GSK, this simplification of the immunization process could help increase vaccine uptake and make it easier for healthcare professionals to administer. The non-liquid form of Menveo has been in use for over a decade in more than 60 countries, including throughout the European Union, and has been widely distributed, with over 82 million doses administered since its introduction.
IMD is a rapidly progressing disease, with GSK noting that one in six individuals who contract IMD will die, sometimes within 24 hours. Additionally, one in five survivors may experience long-term consequences, such as neurological damage, amputations, hearing loss, and other nervous system issues. The approval of the liquid version of Menveo aims to enhance efforts to prevent this devastating disease and safeguard vulnerable populations in Europe.
By providing an easier-to-administer vaccine, GSK aims to expand access to life-saving immunization against meningitis and septicaemia, particularly in at-risk groups across the European Union.
